$4.5M ‘Non-Drowsy’ Robitussin Settlement: Official Website Is Live

New to ClassAction.org? Read our Newswire Disclaimer

GlaxoSmithKline Consumer Healthcare Holdings and GSK Consumer Health have agreed to pay a $4.5 million settlement to resolve a consolidated class action lawsuit over allegations that certain Robitussin products were deceptively labeled and sold as “non-drowsy.”

Don’t miss the next class action settlement deadline. Sign up for ClassAction.org’s free weekly newsletter.

The official website for the “non-drowsy” Robitussin class action settlement can be found at NonDrowsyRobitussinSettlement.com.

The $4,500,000 deal, which was preliminarily approved by the court on January 23, 2025, will resolve claims that the companies—now known as Haleon US Holdings and Haleon US Inc., respectively—misrepresented the products given that they contain dextromethorphan (DXM), an ingredient the Robitussin lawsuit argued causes drowsiness.

The Robitussin settlement covers anyone who purchased, for personal or household use and not for resale, any flavor Robitussin product containing DXM and marketed as “non-drowsy” in the United States between February 16, 2016 and January 21, 2025.

A list of qualifying Robitussin products can be found on this page or on the settlement website’s FAQs page.

Money from the Robitussin settlement fund will be distributed on a pro rata basis to class members who submit a valid claim form online or by mail by May 12, 2025.

Related Reading: ‘Non-Drowsy’ Robitussin Contains Active Ingredient Known to Cause Drowsiness, Class Action Says

To receive a Robitussin settlement rebate, you can file a claim online on this page. You will need to provide your unique Notice ID and confirmation code, which can be found on the personalized settlement notice you may have received by mail or via email. You can still submit a claim form online if you did not receive a notice.

Alternatively, you may download the PDF claim form or contact the settlement administrator to request a paper copy to return by mail.

According to the settlement website, individual payout amounts are estimated to range between $1.50 and $4.75 per valid claim, though final figures will depend on the total number of valid claims that are submitted.

Class members may submit one claim per household without proof of purchase and up to three claims per household with proof of purchase, the site says.

As part of the settlement agreement, Haleon will also exclude the “non-drowsy” claim from product labels, marketing and advertisements going forward, the website adds.

The parties now await a hearing scheduled for June 30, 2025, at which the court will determine whether to grant final approval to the terms of the deal.

Robitussin settlement payouts will be issued to eligible consumers only if the deal receives ultimate approval and after any appeals are resolved, the website shares.

Check out ClassAction.org’s free legal resources to learn how to start a class action lawsuit.